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Ovarian cancer is a heterogeneous disease of the female re-
productive tract which, despite its relatively low incidence
in developed countries, carries a poor prognosis. Despite
advances in the detection and treatment of ovarian cancer,
it remains the 5th leading cause of cancer death in women
[1]. Epithelial ovarian cancer (EOC) comprises 90% of all
ovarian cancer cases [2]. Type I EOC primarily consists of
low-grade serous, mucinous, endometrioid and clear cell
subtypes, and is characterized as slow growing with intact
DNA repair machinery [3]. Type II EOC, also known as
high-grade serous ovarian cancer, comprises 70% of EOC
cases [4] and is characterized by rapid growth with no
identified precursor lesions, and genome instability (p53
loss) [5]. The molecular events underlying Type II EOC re-
main poorly understood, and despite initial response to
chemotherapy, these tumors often recur with chemo-
resistance. EOC is typically diagnosed at late stage, when
the tumor has spread beyond the pelvic region into the
peritoneal cavity, making complete surgical removal ex-
tremely difficult. Despite recent advances in surgery and
adjuvant chemotherapeutics, the overall five-year survival
rate for EOC remains at only 40%, in part due to common
and rapid peritoneal spread of disease, indicating the need
to understand the genetic and epigenetic events underlying
EOC progression.
We recently identified that the CpG island-associated
promoter of ZNF300P1, a candidate long-intergenic non-
coding (linc) RNA, was hypermethylated in EOC cell lines,
and this was associated with loss of expression [6]. LincR-
NAs are polyadenylated RNA transcripts that are tran-
scribed by RNA polymerase II and do not encode for
protein, although they do carry epigenetic signatures simi-
lar to those found in protein-coding genes [7]. In cancer,
recent studies have demonstrated a link between lincRNA
expression and disease progression and outcome related to
the role of lincRNAs in gene expression regulation [7,8].
ZNF300P1, also known as LOC134466, is a pseudo-
gene of the human zinc finger protein ZNF300 (sharing
89% identity), and is characterized as a non-coding tran-
script. Khalil and colleagues identified ZNF300P1 as a
lincRNA using a computational algorithm that elimi-
nates transcripts with protein-coding domains and chro-
matin signatures that reflect transcribed genes [9]. Our
evaluation showed that ZNF300P1 expression was also
repressed in human EOC tissues compared to normal
ovarian surface epithelial cells (OSE) [6]. Quantitative
methylation analysis discriminated 27 EOC tumors from
14 normal OSE samples with a high degree of accuracy
(81% sensitivity, 92% specificity [6]), suggesting its poten-
tial as an EOC biomarker. Finally, methylation-specific
headloop-suppression PCR (MSH-PCR) screening of 159
high-grade EOC tumors demonstrated methylation of
ZNF300P1 in 81% of tested tumors, suggesting that itmay serve a functional role in EOC [6]. Indeed, studies
have demonstrated that lincRNAs, including ZNF300P1,
are associated with Polycomb Repressive Complex (PRC2)
and CoREST chromatin modifying complex proteins [9],
supporting the notion that ZNF300P1 may be involved in
gene expression regulation and thus may serve a func-
tional role in cancer and other processes.
The function of ZNF300P1 is currently unknown. Since
ZNF300P1 is frequently and specifically methylated and
down-regulated in EOC, we sought to examine its poten-
tial role in regulating cell behavior in EOC. Our findings
suggest that ZNF300P1 is frequently methylated in EOC
and reveal a novel function for ZNF300P1 in regulating
cell polarity, motility, and adhesion.
Results
ZNF300P1 is epigenetically repressed in ovarian cancer
We have previously demonstrated long-range epigenetic
silencing (LRES) of discrete genomic regions in colorectal
and prostate cancer [10-12]. Regional repression is associ-
ated with DNA hypermethylation and/or chromatin re-
modeling of consecutive genes along the DNA strand. To
investigate whether ZNF300P1 methylation was embed-
ded in a region of LRES in EOC, we evaluated methylated
DNA immunoprecipitation on whole genome promoter
tiling array (MeDIP-ChIP) profiles for normal ovarian sur-
face epithelium (OSE) and A2780 and CaOV3 cancer cell
lines as described ([6]) (Figure 1A). Evidence of hyperme-
thylation at the CpG island associated with ZNF300P1
was observed in both cancer cell lines, however hyperme-
thylation of neighboring CpG islands (ZNF300 and GPX3)
was only observed in A2780 cells. The transcript profiles
from the same study showed that this hypermethylation
was indeed associated with repression of gene expression
(Additional file 1: Figure S1A), suggesting that regional
epigenetic silencing may occur near ZNF300P1 in ovarian
cancer. To investigate the frequency of surrounding CpG
island methylation in further cell lines, Sequenom assays
were designed to interrogate the methylation of five CpG
islands associated with nearby genes DCTN4, MST150,
ZNF300, GPX3 and TNIP1 genes. Methylation levels were
evaluated for the five islands, as well as that for
ZNF300P1, in 10 EOC cell lines and 2 immortalized
OSE cell lines (Figure 1B). The CpG island for GPX3,
located 3′ of ZNF300P1, exhibited methylation in 5/10
EOC cell lines and 1/2 OSE cell lines tested and the
CpG island for ZFN300, located 5′ of ZNF300P1, was
methylated in 3/10 EOC cell lines and 0/2 OSE cell
lines. The largest region of neighboring CpG island
methylation was observed in three cell lines: IGROV1,
A2780 and TOV21G, with up to 150 kb of flanking
methylation (ZNF300-GPX3). This genomic size is smaller
than average for regions characteristic of LRES, which are






















































































































Figure 1 ZNF300P1methylation patterns in EOC. (A) MeDIP-Chip methylation tracks (vertical bars denote methylation score of 1–5) of A2780 (red)
and CaOV3 (purple) EOC cell lines compared to grouped profiles of three OSE (green) mapped to chromosome 5q33.1. Features of the chromosomal
region are also shown including strand specific genes (black), CpG islands (dark green) and the Sequenom assay designed to interrogate promoter
methylation (blue). (B) Average promoter methylation (% methylation as heatmap) of CpG islands flanking ZNF300P1 in EOC cell lines and immortalized
OSE. Genes are sorted 5′ to 3′ on chromosome 5q33.1, cell lines are organized by similarity in methylation patterns. (C) Boxplot comparing average
promoter methylation of ZNF300P1 in the eight clear cell tumors compared to 19 OSE. The p-value is generated by a Mann–Whitney U test.
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lation in up to 6 of 12 cell lines, none were as frequently
methylated as ZNF300P1 (10/10 EOC cell lines and 1/2
OSE) (Figure 1B). This result suggests that methylation of
ZNF300P1 is the key initiating event, rather than a part of
LRES, in this region that can then spread in some cell
lines [13]. We therefore performed a detailed analysis of
methylation of ZNF300P1 in primary ovarian tumors to
determine its tendency in clinical EOC samples.
ZNF300P1 methylation is not limited to serous subtypes
of EOC
While high-grade serous tumors comprise the majority of
EOC, the less common and molecularly distinct clear cellsubtype (5%) [14], if diagnosed at late stage, carries an ex-
tremely poor prognosis [15]. Therefore, to evaluate whether
methylation was conserved in this histological subtype,
ZNF300P1 methylation was investigated in 8 clear cell
tumor samples by Sequenom and compared to methylation
in 19 OSE samples (Figure 1C). ZNF300P1 hypermethyla-
tion (>50% average promoter methylation) was observed in
4 of the 8 clear cell tumors with methylation levels sig-
nificantly higher in tumors than OSE (p-value <0.001).
This result indicates that the frequency of ZNF300P1
hypermethylation is comparable between clear cell and
serous EOC [6], and significantly higher than in OSE.
These findings suggest that methylation of ZNF300P1
may not be a unique feature of Type II EOC.
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immortalized ovarian epithelial cells.
Having originally identified ZNF300P1 repression as a
common feature of EOC and other cancer types, we
sought to evaluate its biological impact in the immortal-
ized normal ovarian cell line HOSE17.1, which is derived
from normal ovarian surface epithelium and which ex-
presses high levels of ZNF300P1 and exhibits limited
methylation [6]. As a candidate lincRNA, we hypothe-
sized that a reduction of ZNF300P1 expression, as seen
in ovarian cancer cell lines (Additional file 1: Figure
S1B), would recapitulate transcriptional network and the
cell phenotype aberrations observed in cells harboring
ZNF300P1 DNA methylation. To test this, we analyzed
RNA transcript profiles of HOSE17.1 cells following
siRNA-mediated knockdown of ZNF300P1 (HOSE17.1-
siZP1). To ensure that expression of the highly homolo-
gous ZNF300 is not affected upon knockdown of
ZNF300P1, we compared expression of ZNF300 in
HOSE 17.1-siZP1 knockdown cells and non-targeting
control knockdown cells (HOSE 17.1-siNTC) by both
microarray and qPCR (Additional file 2: Figure S2A).
Our results demonstrate that expression of ZNF300 is
not altered upon knockdown of ZNF300P1, suggesting
that any gene expression changes detected in the
knockdown cells are due specifically to repression of
ZNF300P1. A total of 752 genes (509 up-regulated and
243 down-regulated) were identified that exhibited
≥1.3-fold (p-value < 0.01) differential expression upon
knockdown of ZNF300P1. To validate our microarray
analysis, we chose nine genes, based on statistical sig-
nificance and functional annotation, for validation by
qPCR (Additional file 2: Figure S2B). Most of these
genes demonstrated differential expression by qPCR in
knockdown cells compared with controls, confirming
the microarray results.
Ingenuity Pathways Analysis™ (IPA) was utilized to
identify gene networks and functions altered by down-
regulation of ZNF300P1 (Table 1). The top gene network
affected by repression of ZNF300P1, Cell Cycle, DNA
Replication, Recombination, and Repair, Cell-To-Cell
Signaling and Interaction (score = 41, Table 1), is pre-
sented in Additional file 2: Figure S2C. The top disease
network affected was cancer (186 molecules, p = 0.016,
Table 1) and the top molecular function was cellular
movement (80 molecules, p = 0.017, Table 1). These data
implicate ZNF300P1 repression in diverse molecular
pathways commonly perturbed in cancer.
To further investigate the nature of these molecular
aberrations, functional annotation (DAVID) of gene ontol-
ogy term (GO-term) enrichment and KEGG pathways as-
sociated with these expression changes were evaluated in
the 752 genes de-regulated by ZNF300P1 knock-down
(Table 1). KEGG pathway analysis showed that the topcanonical signaling pathways up regulated following
ZNF300P1 repression were focal adhesion, and the re-
lated ECM-receptor interactions pathway. Evidence of
repression of the NOD-like pathway suggested that cell
death pathways were being perturbed. Interestingly,
GO-terms for cellular adhesion were enriched in the
up-regulated gene list (complementing the KEGG ana-
lysis), whereas terms associated with cell cycle were
enriched in the down-regulated gene list (Additional
file 3: Table S1). These data suggested that ZNF300P1
repression results in activation of cellular movement
and repression of cell cycle processes.
Loss of ZNF300P1 is associated with phenotypic and cell
behavior changes
Transcriptome analysis indicated that ZNF300P1 knock-
down results in decreased expression of genes involved
in cell cycling. We sought to determine the role that
ZNF300P1 might play on cancer cell processes including
proliferation and motility. Our first step towards defin-
ing a functional role for ZNF300P1 was to determine the
cellular localization of the lincRNA in HOSE17.1 cells.
As demonstrated in Figure 2A, our studies reveal that
ZNF300P1 is enriched in the nucleus, lending further
support to a potential functional role in ovarian cancer.
We next evaluated cell proliferation and colony forma-
tion in normal HOSE 17.1 cells in which ZNF300P1 ex-
pression was knocked-down (HOSE17.1-siZP1). Expression
analysis of ZNF300P1 transcript levels following siRNA
treatment showed a maximal knockdown of ~50% over
72 hours post transfection with increased variation at
96–120 hours (Additional file 1: Figure S1C). Prolifera-
tion assays showed that ZNF300P1 knockdown results
in decreased cell growth, with HOSE17.1-siZP1 cells
entering log-phase growth later relative to control
(HOSE17.1-siNTC) cells (Figure 2B). These results were
validated in colony formation assays, which showed that
HOSE17.1-siZP1 cells had impaired colony formation
(Figure 2C). However, HOSE17.1-siZP1 cells displayed no
defect in cell cycle, by propidium iodide staining and flow
cytometry (Additional file 4: Figure S3), nor were prolifer-
ation differences explained by increased cell numbers in
the supernatant of the culture vessel (data not shown), in-
dicating no obvious cell cycle defects nor altered sensitiv-
ity to anoikis. Together, these results show that the gene
networks associated with the cell cycle altered following
ZNF300P1 knockdown manifest as a reduction in popula-
tion growth, but show no evidence of cell-cycle blocks nor
altered anoikis-related cell death.
IPA identified cellular movement as the top molecular
function significantly altered by ZNF300P1 knockdown
(Table 1). We therefore next sought to investigate the ef-
fect of ZNF300P1 knockdown on cell adhesion and mo-
tility in HOSE17.1 cells. Boyden chamber trans-well
Table 1 Ingenuity pathway analysis in cells by down-regulation of ZNF300P1
Ingenuity pathway analysis: top functions
p-value # molecules
Top Network: Cell Cycle, DNA Replication, Recombination,
and Repair, Cell-To-Cell Signalling and Interaction
Top Disease: Cancer 1.61E-02 186
Top Molecular Function: Cellular Movement 1.68E-02 80
Genes Up Regulated: KEGG Pathways
Count % Fold- Enrichment corrected p-value
hsa04510: Focal adhesion 16 4.35 4.17 0.000
hsa04512: ECM-receptor interaction 8 2.17 4.99 0.047
Genes Down Regulated: KEGG Pathways
Count % Fold- Enrichment corrected p-value
hsa04621: NOD-like receptor signalling pathway 7 3.23 7.97 0.022
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between HOSE17.1-siZP1 cells and HOSE17.1-siNTC
cells (data not shown). However, live cell tracking of
HOSE17.1-siZP1 and HOSE17.1-siNTC cells during
wound healing showed a clear defect in persistent migra-
tion (defined as the total distance covered by the cell
divided by the Euclidean distance covered) into the
wound space by HOSE17.1-siZP1 cells (Figure 2D, E and
Additional file 5: Movies 1 and 2). In order to test
whether this defect was due to a loss in the cells’ ability
to polarize the cytoskeleton relative to the wound space,
immunofluorescence of Golgi orientation relative to the
nucleus, cytoskeleton and wound space was quantified
in HOSE17.1 cells 6 hours following wounding (Figure 3A).
The results demonstrate a significant decrease in the num-
ber of cells with the Golgi arranged towards the directional
front in HOSE17.1-siZP1 cells, consistent with a defect in
cellular polarity in these cells.
A hallmark and major cause of mortality of EOC is the
spread of cancer cells from the ovary to sites within the
peritoneal cavity. We have shown that DNA methylation-
associated repression of ZNF300P1 occurs commonly in
EOC, and that the repression of this lincRNA in epithelial
ovarian cells results in a defect in cell polarity, which may
contribute to metastasis. Thus, to further explore the po-
tential influence of ZNF300P1 on this crucial step in EOC
progression, we tested the capacity of cells to adhere to
mouse peritoneal tissue, using an ex vivo peritoneal adhe-
sion assay. HOSE17.1 cells with repressed ZNF300P1 ex-
pression demonstrated significantly increased peritoneal
adhesion compared with HOSE17.1-siNTC cells (p-value
<0.05 Mann–Whitney U-Test) (Figure 3B), implicating
ZNF300P1 loss, as commonly seen in EOC cases, in pro-
moting adhesion of EOC cells to peritoneal surfaces, thus
potentially a contributing factor to the metastatic spread
of EOC.Discussion
We have previously demonstrated that methylation of
the lincRNA ZNF300P1 is a potential biomarker in EOC
[6]. Here, we investigate the novel role that ZNF300P1
repression may play in ovarian cancer development and
progression, and show that lincRNA ZNF300P1 plays a
role in regulating cell polarity, and how loss of expres-
sion may contribute to the metastatic potential of ovar-
ian cancer cells.
LincRNAs are gaining increasing importance both as
biomarkers in cancer (HOTAIR: breast [8], liver [16],
pancreas [17]; MALAT-1: NSCLC [18]; PCAT-1: pros-
tate [7]), and as regulators of complex and diverse bio-
logical functions. Guttman et al. developed a screen to
identify lincRNAs using histone methylation markers
H3K4 and H3K36 to demarcate transcribed RNAs lo-
cated outside of protein coding regions [19]. Khalil and
colleagues applied this approach in human cells, and
identified ZNF300P1 as a lincRNA and used RIP-Chip to
show its association with Polycomb Repressive Complex
(PRC2) and CoREST chromatin modifying complex
proteins, indicating the potential for ZNF300P1 to be
involved in modification of chromatin structure [9].
LincRNAs have also been proposed to alter transcrip-
tional networks using four modes of action [20]. These
are: 1) as decoys to titrate DNA-binding proteins (or miR-
NAs [21]); 2) as scaffolds to bring proteins together within
a complex; 3) as guides to recruit proteins, such as chro-
matin modification complexes to DNA; or 4) as enhancers
to bring distal portions of the genome into close proximity
through looping. The transcriptional analyses undertaken
within this study, using siRNA against ZNF300P1, indicate
that loss of ZNF300P1 expression, as seen resulting from
hypermethylation in ovarian cancer samples, results in
both up- and down- regulated gene expression (Additional























































































































































Figure 2 ZNF300P1 cellular localization and phenotypic changes. (A) MALAT1 and GAPDH are included as nuclear and cytoplasmic
transcript controls, respectively. Data is presented as mean of 3 independent experiments ± S.D. The effect of ZNF300P1 knockdown on HOSE17.1
cells. (B) Representative population growth of HOSE17.1 cells following transfection with non-targeting control (HOSE17.1-siNTC; dark grey) or
siRNA against ZNF300P1 (HOSE17.1-siZP1; light grey). A line of best fit is shown for both conditions. (C) Representative colony formation at 10 days
post-transfection. Each data point represents total number of colonies per 4 wells. (D) Windrose plots of cell migration patterns following an
in vitro wound healing assay. Cell starting position is designated as 0,0 and the path taken over 24 hours is measured every 10 minutes (μm).
(E) Boxplot of persistent migration ratios for individual cells from a representative experiment. Persistence was defined as the ratio of the
total path length divided by the Euclidean displacement. P-values are generated by a Mann–Whitney U test.
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scope of this study, it is possible that ZNF300P1 suppres-
sion may alter transcriptional networks via modification
of chromatin, guiding the repressive complex to genes/
promoters to regulate their transcription.
However, a number of recent studies have also pro-
posed that a sub-population of lincRNAs arise from
pseudogenes [21,22], and act as endogenous competi-
tors, altering the distribution of miRNA molecules on
their targets [21]. ZNF300P1, also known as LOC134466,
is a pseudogene of the human zinc finger protein
ZNF300. Little is known of the function of this nucleus-
restricted transcription factor [23]. Demonstrated to be
up-regulated in cancer biopsies [24], ZNF300 binds the
sequence C(t/a)GGGGG(g/c)G, found in the promoterregions of genes including IL-2, IL-2Rb, CD44, p53,
TNF-a, and TRAF2, which play crucial roles in various
tumorigenic and inflammatory processes. Furthermore,
ZNF300 induces the NF-kB pathway, in turn inducing
IL-6 and IL-8, potentially exacerbating inflammation and
promoting tumor metastasis [24]. One potential means
by which lincRNAs arising from pseudogenes have been
proposed to function is by acting as a decoy for miRNAs
targeting the protein-coding gene. Given that ZNF300
is up-regulated in cancer, and promotes inflammation
and metastasis, the repression of ZNF300P1 associated
with methylation in ovarian cancer make it unlikely
to be functioning as an miRNA decoy. Furthermore,
our analysis of ZNF300 expression upon ZNF300P1 silen-





















































































Figure 3 Effect of ZNF300P1 knockdown on cell polarity and
adhesion. (A) Stacked barchart of Golgi body orientation relative to
woundspace and the nucleus 6 hrs after wounding in vitro. Cells
were visually scored as having Golgi in the front quarter of the cell
(generally considered a polarised orientation), or the back quarter, or
sides. Data is mean of 3 independent experiments ± S.D. (B) Boxplot
of ex vivo peritoneum adhesion assays. The number of cells adhered
to mouse peritoneum after 3 hrs was counted per field, data is
mean of 3 independent experiments ± S.D. The p-value is generated
by a Mann–Whitney U test.
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that ZNF300P1 acts as an endogenous decoy for miRNAs
targeting ZNF300.
Notably, we have confirmed nuclear enrichment of
ZNF300P1 (Figure 2A) [23], and have shown that loss of
ZNF300P1 expression in ovarian cells results in the perturb-
ation of several key pathways involved in cell cycle, cell
movement, and cell-to-cell signaling and interaction (Table 1
and Additional file 2: Figure S2C). These results suggest that
DNA hypermethylation of the promoter CpG island of
ZNF300P1 may play a key role in the malignant progression
of ovarian cancer. While repression of the lincRNA clearly
affected the ability of cells to proliferate and form colonies,
it had no discernible effect on the cell cycle, indicating that
ZNF300P1 does not function as a classic tumor suppres-
sor. Interestingly, ZNF300P1 was recently identified as
methylated in small cell lung cancer-derived cell lines [25]
potentially indicating that loss of expression of this tran-
script may be common to several cancer types.
The major phenotypic outcomes we identified to be
associated with ZNF300P1 silencing was decreased po-
larity and the resultant loss of migratory persistence
(Figures 2 and 3), both key in cancer development and
the aberrant spread of cancer cells [26]. These pheno-
types, together with the enhanced ability of HOSE17.1
cells lacking ZNF300P1 to adhere to mouse peritoneum,
may provide an advantage for cells to more efficiently
colonize the peritoneal tissue, thus reducing the efficacy
of surgical treatment in EOC.Conclusions
We have demonstrated that the lincRNA ZNF300P1 is
frequently hypermethylated and silenced in ovarian can-
cer. We have determined that suppression of ZNF300P1
in ovarian cancer cells results in decreased proliferation
and colony formation, as well as loss of cellular polarity.
We also reveal a novel role for ZNF300P1 in the adhe-
sion of ovarian cancer cells to the peritoneal membrane,
suggesting a potential function in ovarian cancer metasta-
sis. Together, these results provide the first evidence of the
downstream biological effects of methylation-mediated re-
pression of ZNF300P1 in ovarian cancer, and implicate the
specific targeting of the transcript, and the resultant loss of
expression, as a critical step in EOC progression.
Methods
Cell line, tissue and OSE collection and processing
Ten standard cancer cell lines derived from various sub-
types of EOC: serous (SKOV3, OVCAR3, IGROV, OV90,
COLO316, A2780 and CaOV3), endometrioid (TOV112D),
clear cell (TOV21G) and mucinous (EFO27), as well as two
human immortalized OSE cell lines (HOSE 6.3 and HOSE
17.1), were obtained and cultured as described previously
[6,27]. Fresh-frozen tumor (FFT) samples were obtained
with written informed consent from women undergoing
debulking surgery for EOC at the Royal Hospital for
Women (RHW, Sydney, Australia), snap frozen in liquid
nitrogen and stored at −80°C. Clinico-pathological charac-
teristics of patient samples are presented in Additional file
6: Table S2. Pathologically normal OSE cell samples were
obtained with written informed consent, by brushing the
ovary during surgery for non-ovarian gynecological malig-
nancies followed by expansion of epithelial cells in culture.
Cultures were evaluated for purity by staining for high mo-
lecular weight cytokeratin to exclude stromal contamin-
ation and maintained in culture as previously described
[28]. Cell pellets from passage 3 or earlier were processed
for DNA extraction. Experimental procedures were ap-
proved by the Human Research Ethics Committee of the
Sydney South East Area Hospital Service Northern Section
(00/115).
Nucleic acid extraction and processing
Total RNA was extracted with Trizol (Invitrogen) or
RNeasy mini kit (Qiagen). Genomic DNA was extracted
from tumor and OSE with QiaAMP mini kits (Qiagen),
from FFPE tissue with Gentra Puregene DNA isolation
kit (Qiagen) and from cell lines with the Stratagene
DNA extraction Kit (Agilent). 1–2 μg genomic DNA iso-
lated from human blood (unmethylated control, Roche
Applied Sciences), in vitro methylated DNA (Chemicon
International) and RNase-treated cell and tumor DNA
was bisulphite-converted either using the Epitect kit
(Qiagen) or as previously described [29,30].
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Sequenom methylation PCR assays were designed accord-
ing to [31] to interrogate methylation levels at CpG islands
immediately upstream (DCTN4, MST150 and ZNF300)
and downstream (GPX3 and TNIP1) of ZNF300P1. Primers
(Additional file 7: Table S3) were optimized for bisulphite-
converted DNA specificity, and tested for bias using a ther-
mal gradient on mixes of 50:50 methylated: unmethylated
template. Triplicate PCR reactions were pooled, and ap-
plied to spectrochips according to manufacturer’s instruc-
tions for MALDI-TOF analysis (Sequenom). Results were
analyzed using epityper software and RseqMeth [32] CpG
methylation levels were averaged across the amplicon to
determine average methylation.
Methylation-specific headloop-suppression PCR assay
(MSH-PCR)
Methylation specific headloop-suppression assays (MSH-
PCR) were performed as previously described [6]. Briefly,
triplicate MSH-PCRs were performed on bisulphite-
converted DNA from FFPE tissue samples. By normaliz-
ing the signal to SFN, which is methylated in all samples
[33], or bisulfite-converted genomic DNA (rDNA), relative
methylation was calculated for all samples.
Knockdown conditions and transfection of siRNA
Colloidal suspensions of 25 nM ZNF300P1 (Ambion
#n263234) or non-targeting control (NT-C; Ambion
#4390483) siRNA in Lipofectamine 2000 and opti-MEM
(Invitrogen) were prepared for transfecting HOSE17.1 cells
according to Lipofectamine 2000 transfection protocol.
Peak knockdown of ~50% was observed in HOSE17.1 cells
by qPCR (Primer sequences, see Additional file 7: Table
S3) at 48–72 hours post transfection (Additional file 1:
Figure S1C).
Transcript profiling
Biological triplicate RNA samples from 72 hours post
transfection with 25 nM siRNA were submitted to the
Ramaciotti Centre (University of New South Wales) for
transcription, labeling and application to Affymetrix
Human Gene 1.0ST mRNA transcript-profiling arrays.
Data analysis
Array data were evaluated using the LIMMA package ei-
ther in GenePattern (Broad Institute, Cambridge MA,
USA) or in the R environment [34]. Briefly, array CEL files
were normalized and background-corrected by the RMA
method. Differential expression between probe-sets in
triplicate control or ZNF300P1 siRNA arrays was calcu-
lated using Bayesian linear models with stringency cut-offs
of 1.3 fold up or down following knockdown, with an un-
adjusted p-value of <0.01. Evaluation of gene list proper-
ties was performed using Functional annotation (GOterms and KEGG pathways) and gene networks in Ingenu-
ity Pathway Analysis™ software.
Transcript localization
Nuclear and cytoplasmic RNA was isolated using Ambion’s
PARIS kit, according to the manufacturer’s instructions.
qRT-PCR was performed using MALAT1 and GAPDH as
nuclear- and cytoplasmic-enriched controls, respectively.
ZNF300 and ZNF300P1 RNA levels were determined in
HOSE17.1 cells transfected with siRNAs either against
ZNF300P1, or a control sequence.
Expression quantitative real-time PCR (qPCR)
qPCR assays for 18 s rRNA (cat# Hs99999901_s1),
GAPDH (cat# Hs99999905_m1),ZNF300P1 (cat# Hs008-
59547_m1), ZNF300 (cat# Hs04177113_m1) and MALAT1
(cat# Hs00273907_s1) were purchased from Applied Biosys-
tems and utilized for measuring gene expression. SYBR
green qPCR assays were designed in PrimerExpressTM (Life
Technologies; sequences in Additional file 7: Table S3)
Population growth curves
HOSE17.1 cells treated with ZNF300P1 or NT-C siRNA
were seeded at 2.5x103 cells/cm2 (population growth as-
says) or 600 cells/cm2 (colony formation). At indicated
times, cells were fixed and stained using Diff Quick (Lab
Aids). For quantitation, 10% acetic acid was used to de-
stain the plates, and absorption measured at 595 nm.
Wound healing: polarity assay and live cell tracking
Transfected cells were plated either onto glass coverslips
(polarity assays), or into 6/12 well plates (live cell tracking),
to reach confluence at 48 hrs post transfection. Using a
20 μl pipette tip, a wound was made in each monolayer,
cells rinsed twice with medium, and incubated for 6 hrs
(polarity assay) at 37°C, or into the heated chamber of a
Zeiss Inverted microscope (live cell tracking). For polarity
assays, cells were fixed using 4% PFA, and Golgi were
stained using an anti-gm130 antibody (BD Biosciences,
cat# 610823, 1/100 dilution), followed by alexa fluor-
conjugated secondary, and counter-stained using phalloidin
and DAPI. Slides were imaged using AxioVision (version
4.7) software, and Golgi orientation (relative to nucleus and
wound space) determined using ImageJ software. For time-
lapse photography, cells were imaged at 10 minute intervals
over 24 hours by a Zeiss Axiovert 200 M inverted micro-
scope and Image J software was used to track cell nuclei.
Ex vivo peritoneal adherence assay
Ovarian cancer cell peritoneal adhesion was determined
using an ex vivo assay, modified from previous studies
[35]. Briefly, the peritoneal tissue was excised from eutha-
nized 10–12 wk female Balb/c mice, divided along the
midline into two pieces and placed into serum-free media.
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tion were added to 96-well plates and peritoneal tissue laid
over the wells, mesothelial surface down. The tissue was
then covered by a glass coverslip and the inverted plate
was incubated for 3 hrs at 37°C. The peritoneal tissue was
then washed with serum-free medium, and attached cells
observed and imaged using a Leica MZ16FA fluorescent
dissection microscope, attached to a Leica DFC420C cam-
era. Image J was used to count 6–9 fields per well.
Additional files
Additional file 1: Figure S1. (A) Raw expression values of genes
associated with CpG islands flanking ZNF300P1. Data is from Affymetrix
HGU133 Plus 2 transcript profiles for A2780 and CaOV3 cancer cell lines
[6]. (B) Comparison of repression vs methylation in OSE cells (adapted
from [6]). (C) The effect of ZNF300P1 knockdown by siRNA on transcript
levels relative to non-targeting control. Data is mean of 3 independent
experiments ± S.D.
Additional file 2: Figure S2. (A) ZNF300 and ZNF300P1 expression by
microarray and qPCR following ZNF300P1 knockdown by siRNA, relative to
non-targeting control. Data is mean of 3 or 4 independent experiments ± S.D.
*p-value < 0.05 by student’s t-test. (B) qPCR validation of selected differentially
expressed genes in HOSE17.1-siZP1 vs siNTC. Expression values are relative to
GAPDH and error bars represent the average ± SD of 3 replicate experiments.
(C) Top IPA™ gene network perturbed by ZNF300P1 repression in HOSE17.1
cells. Relative fold-change for each gene is shown by color (red indicates
down-regulated and green represents up-regulated genes) following
knockdown. *duplicate probe-set expression score is reconciled.
Additional file 3: Table S1. Gene Ontology (GO) Process in cells by
down-regulation of ZNF300P1.
Additional file 4: Figure S3. Propidium iodide (PI) staining showing
proportion of cells in stages of the cell cycle with relative proportions of
populations over 3 replicate experiments ± SD.
Additional file 5: Movies 1 and 2: HOSE17.1 cells transfected with
either siNTC (Movie 1) or siZP1 (Movie 2) were grown to
confluence, 72 hours post transfection. A wound space was made
using a 20μL pipette tip, cells washed twice with fresh media, and then
the plate transferred to the incubator chamber of the microscope.
Imaging was performed from approximately 5 hours post wounding, and
frames captured every 10 minutes, over a 24 hour period. Movies were
generated from these images, and play at 20 frames/second.
Additional file 6: Table S2. Clinico-pathological features of clinical
samples assayed in this study.
Additional file 7: Table S3. Primer Sequences for qPCR assays used in
this study.
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